As scientists have a deeper insight into the CXCL12-CXCR4 axis in MM, a phase I/II clinical research innovatively combined plerixafor with bortezomib to sensitize MM cells and improve outcomes [6]. This evidence concerns the gene CXCR4 and Miyoshi myopathy.